Identification of a moxidectin dose for 4- to 11-year-old children to support registration and potential use for onchocerciasis elimination: results of an open-label pharmacokinetic and safety study

Identification of a moxidectin dose for 4- to 11-year-old children to support registration and potential use for onchocerciasis elimination: results of an open-label pharmacokinetic and safety study

Abstract Background The WHO and onchocerciasis-endemic countries target elimination of the transmission of Onchocerca volvulus, the parasite causing onchocerciasis, primarily through ivermectin mass drug administration (MDA). In Africa, alternative treatment strategies are required to achieve or acc...

Full description

Saved in:
Bibliographic Details
Main Authors: Nicholas O. Opoku, Felix Doe, Mannel E. Agbogah, Rukaya Laryea, Shelter K. Gordor, Bismark S. Donkor, Edwin Anyomitse, Dickson Kugali, Mariëlle van Zutphen-van Geffen, Danielle J. Navarro, Craig R. Rayner, Kashyap Patel, Annette C. Kuesel, Melinda Lowe, Sally Kinrade
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Parasites & Vectors
Subjects:
Onchocerciasis
Moxidectin
Paediatric use
Doses for 4-to 11-year-old children
Ghana
Online Access:https://doi.org/10.1186/s13071-025-06891-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13071-025-06891-z

Similar Items